Emerging therapeutic targets in multiple sclerosis

被引:23
作者
Fontoura, Paulo
Steinman, Lawrence
Miller, Ariel [1 ]
机构
[1] Technion Israel Inst Technol, Rappaport Fac Med, Multiple Sclerosis & Brain Res Ctr, IL-34362 Haifa, Israel
[2] Technion Israel Inst Technol, Res Inst, Inst Technol, Dept Neurol,Carmel Med Ctr, IL-34362 Haifa, Israel
[3] Univ Nova Lisboa, Fac Med Sci, Dept Immunol, P-1200 Lisbon, Portugal
[4] Beckman Ctr Mol Med, Interdept Program Immunol, Dept Neurol & Neurol Sci, Stanford, CA USA
关键词
immunological synapse; immunotherapy; multiple sclerosis; myelin; neuroprotection;
D O I
10.1097/01.wco.0000227035.93199.e0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review The aim of this review is to describe the recent findings regarding the pathogenesis of multiple sclerosis and their translation to new therapies. Recent findings Basic research is providing new insights into the immune elements involved in the pathogenesis of multiple sclerosis both in the periphery as well as in the central nervous system. Unveiling the complex interplay of the molecules-involved in the immunological cascade of the disease supplies new targets for the development of new immunotherapeutic strategies. Similarly, clinical studies and identification of distinct sub groups of patients based on their responsiveness to immunotherapies provides support for the existence,of immunopathological disease subtypes that seem to require different therapeutic approaches. These studies extend the theoretical basis that facilitates development of neuroprotective and repair-promoting therapeutic strategies. Summary The application of novel and cutting-edge technologies in the fields of genomics and proteomics is providing a better understanding of the genetic and environmental factors involved in multiple sclerosis susceptibility and as well as the detection of biomarkers for disease activity and response to therapy. Implementation of these facilitates identification of new targets for therapy towards tailoring treatment to the individual patient with multiple sclerosis..
引用
收藏
页码:260 / 266
页数:7
相关论文
共 67 条
[1]   Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation [J].
Back, SA ;
Tuohy, TMF ;
Chen, HQ ;
Wallingford, N ;
Craig, A ;
Struve, J ;
Luo, NL ;
Banine, F ;
Liu, Y ;
Chang, A ;
Trapp, BD ;
Bebo, BF ;
Rao, MS ;
Sherman, LS .
NATURE MEDICINE, 2005, 11 (09) :966-972
[2]   Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].
Baker, D ;
Pryce, G ;
Croxford, JL ;
Brown, P ;
Pertwee, RG ;
Huffman, JW ;
Layward, L .
NATURE, 2000, 404 (6773) :84-87
[3]   The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity [J].
Bandhuvula, P ;
Tam, YY ;
Oskouian, B ;
Saba, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (40) :33697-33700
[4]   Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis [J].
Ben-Hur, T ;
Einstein, O ;
Mizrachi-Kol, R ;
Ben-Menachem, O ;
Reinhartz, E ;
Karussis, D ;
Abramsky, O .
GLIA, 2003, 41 (01) :73-80
[5]   Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cord [J].
Bradl, M ;
Bauer, J ;
Flügel, A ;
Wekerle, H ;
Lassmann, H .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (05) :1441-1450
[6]   Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis [J].
Bright, JJ ;
Natarajan, C ;
Muthian, G ;
Barak, Y ;
Evans, RM .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5743-5750
[7]   Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis [J].
Cepok, S ;
Rosche, B ;
Grummel, V ;
Vogel, F ;
Zhou, D ;
Sayn, J ;
Sommer, N ;
Hartung, HP ;
Hemmer, B .
BRAIN, 2005, 128 :1667-1676
[8]   Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212 [J].
Croxford, JL ;
Miller, SD .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) :1231-1240
[9]   Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Δ12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis [J].
Diab, A ;
Deng, CS ;
Smith, JD ;
Hussain, RZ ;
Phanavanh, B ;
Lovett-Racke, AE ;
Drew, PD ;
Racke, MK .
JOURNAL OF IMMUNOLOGY, 2002, 168 (05) :2508-2515
[10]   Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin [J].
Dunn, SE ;
Youssef, S ;
Goldstein, MJ ;
Prod'homme, T ;
Weber, MS ;
Zamvil, SS ;
Steinman, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (02) :401-412